If not, don’t worry, you can view the webcast of the Satellite Symposium here.

The Satellite Symposium titled, ‘Improving outcomes for CLL patients – from promising research to current advances in daily practice’ provided an overview of current advances in, and future approaches to, the management of patients with treatment-naïve (TN) or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) using BTK inhibitors (BTKi) and Bcl-2 inhibitors (Bcl-2i). The speakers referenced new treatment guidelines and patient and therapy characteristics such as fit vs unfit patients in the era of targeted therapies, continuous vs fixed duration therapy, and monotherapy vs combination therapy. The Satellite Symposium included patient cases to illustrate how patient and disease characteristics inform treatment selection and sequencing. A summary of novel approaches to targeting Bcl-2 and BTK with the goal of further improving outcomes for CLL patients was also presented.